Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients: Effect of hyperinsulinemia

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 2, 1997, Pages 129-134

  Cella, Giuseppe ^a   Vettor, Roberto ^a   Sbarai, Alessandra ^a   Rossi, Edoardo ^a   Rampin, Ernesto ^a   Macor, Cinzia ^a   Mussap, Michele ^b   Plebani, Mario ^b   Luzzatto, Guido ^a   Girolami, Antonio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Heparin; Hyperinsulinemia; Lipids; Obesity; TFPI

Indexed keywords

HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERINSULINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; OBESITY; PRIORITY JOURNAL; THROMBOSIS;

EID: 8544237727     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996080     Document Type: Article

References (35)

1. Bjorntorp P: Metabolic implications of fat distribution. Diabetes Care 14:1132-1143, 1991.
2. Macor C, A Ruggeri, P Mazzonetto, G Federspil, C Cobelli, R Vetlor: Visceral adipose tissue impairs insulin secretion and insulin sensitivity hut not energy expenditure in obesity. Metabolism 46:123-129, 1997.
3. Bierman EL, JD Brunzell: Obesity and atherosclerosis. In: Bjorntorp P. BN Brodoff (Eds): Obesity. Lippincott, Philadelphia. 1992. pp 512-516.
4. Shimwaki K, M Suzuki, M Ikebuchi, H Takaki, Y Hara, M Tsushima, Y Harano: Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation 92:1749-1757, 1995.
5. Solymoss BC, M Marcil, M Chaour, BM Gilfix, A-M Poitras, L Campcau: Fasting hyperinsulinism, insulin resistance syndrome, and coronary artery disease in men and women. Am J Cardiol 76:1152-1156, 1995.
6. Stout RW: Insulin resistance, hyperinsulinemia, dyslipidemia and atherosclerosis. In: Moller DE (Ed): Insulin Resistance. Wiley, New York, 1993, pp 355-384.
7. Stout RW, EL Bierman, R Ross: Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 36:319-327, 1975.
8. Pfeifle B, H Ditschuncit: Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 20:155-158, 1981.
9. Oppenhaimer MJ, K Sundquist, EL Bierman: Downregulation of high density lipoprotein receptor in human fibroblasts by insulin and IGE-1. Diabetes 38:117-122, 1989.
10. McGill JB, DJ Schneider, CL Arfken, CL Lucore, BE Sobel: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109, 1994.
11. Eliasson M, K Asplund, P-E Evrin, B Lindahl, D Lundblad: Hyperinsulinemia predicts low tissue plasminogen activator activity in healthy population: The Northern Sweden MONICA study, Metabolism 43:1579-1586, 1994.
12. Werling RW, LR Zacharski, W Kisiel, SP Bajaj, VA Memoli, SM Rousseau: Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemostas 69:366-369, 1993.
13. Novotny WF: Tissue factor pathway inhibitor. Semin Thromb Hemostas20:101-108, 1994.
14. Hansen J-B, KR Huseby, N-E Huseby, PM Sandset, T-A Hanssen, A Nordoøy: Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromh Vase Biol 15:879-885, 1995.
15. Sandset PM, U Abildgaard, ML Larsen: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50: 803-813, 1988.
16. Cella G, U Vertolli, A Naso, A Vianello, E Rampin, A Sharai, G Boeri, EW Strauss: Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. Thromb Res 81:671-677, 1996.
17. Harenberg J, R Malsch, M Angelescu, C Lange, H-C Michaelis, H Wolf, DL Heene: Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin. Blood Coagul Fibrinolysis 7:477-483, 1996.
18. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979.
19. De Fronzo RA, JD Tobin. R Andres: Glucose clamp technique: A method of quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979.
20. Bonora E, S Del Prato, RC Bonadonna, G Gulli, A Solini, ML Shank. AA Ghiatas, JL Lancaster, RF Kilcoyne, AM Alyassin, RA De Fronzo: Total body fat content and fat topography are associated differently with in vivo glucose metabolism in non-obese and obese non-diabetic women. Diabetes 41:1151-1159, 1992.
21. Bognacki J, J Hammelburger: Functional and immunologie methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 6:S65-S72, 1995.
22. Jeske W, D Hoppensteadt, J Fareed, E Berems: Measurement of functional and immunologie levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coagul Fibrinolysis 6:S73-S80, 1995.
23. Kokawa T, K-I Enjyoji, K Kumeda, Y-I Kamikubo, M HaradaShiba, H Koh, M Tsushima, A Yamamoto, H Kato: Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vase Biol 16:802-808, 1996.
24. Wiebe DA, SJ Smith: Six methods for isolating high-density lipoproteins compared with use of the reference method for quantifying cholesterol in serum. Clin Chem 31:746-750, 1988.
25. Friedewald WT, RI Levy, DS Fredrickson: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultraccntrifuge. Clin Chem 18:499-502, 1972.
26. Novotny WF, TJ Girard, JP Miletich, GJ Broze Jr: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72: 2020-2025, 1988.
27. Østerud B, MS Bajaj, SP Bajaj: Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemostas 73:873-875, 1995.
28. Yamabe H, H Osawa, H Inuma, M Kaizuka, N Tamura, S Tsunoda, Y Fujita, K Shirato, K Onodera: Tissue factor pathway inhibitor production by human mesangial cells in culture. Thromb Haemostas 76:215-219, 1996.
29. Cella G, A Cipriani, A Tommasini, E Rampin, A Sharai, R Rocconi, G Mazzaro, G Luzzatto: Tissue factor pathway inhibitor antigen plasma level in patients with interstitial lung disease before and after heparin administration. Semin Thromh Hemostas 23:45-49, 1997.
30. Leurs PB, R van Oerle, K Hamulyak, BHR Wolffenbuttel: Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 44:80-84, 1995.
31. Sandset PM, H Lund, J Norseth, U Abildgaard, L Ose: Treatment with hydroxymethylglutaryl-cocnzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 11:138-145, 1991.
32. Hansen J-B, N-E Huseby, PM Sandset, B Svensson, V Lyngmo, A Nordøy: Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 14:223-229, 1994.
33. Kokawa T, T Abumiya, T Kimura, M Harada-Shiba, H Koh, M Tsushima, A Yamamoto, H Kuto: Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 15:504-510, 1995.
34. Zitoun D, L Bara, A Basdevant, MM Samama: Levels of factor VlIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol 16:77-81, 1996.
35. Lindahl AK, U Abildgaard, L Larsen, R Staalesen, AKG Hammer, PM Sandset, O Norfang, TC Beck: Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 62:607-614, 1991.